FCCC LOGO Faculty Publications
de Caceres II , Cairns P
Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction
Clinical & Translational Oncology. 2007 Jul;9(7) :429-437
PMID: ISI:000256942600005   
Back to previous list
Abstract
Molecular studies of many types of cancer have revealed that clinically evident tumours carry multiple genetic and epigenetic abnormalities, including DNA sequence alterations, chromosome copy number changes and aberrant promoter hypermethylation. Together, these aberrant changes result in the activation of oncogenes and inactivation of tumour-suppressor genes (TSG). In many cases these abnormalities can be found in premalignant lesions and even in histological normal adjacent cells. Many tumour types are difficult to detect early and are frequently resistant to available chemotherapy and radiotherapy. Therefore, the early detection, chemoprevention and the design of new therapeutic strategies based on the increased understanding of cancer molecular changes are one of the great challenges nowadays. Insertions of a methyl group at the fifth carbon of cytosines within the dinucleotide 5 ' CpG-3 ' is the best studied epigenetic mechanism. DNA methylation acts together with others mechanisms like histone modification, chromatin remodelling and microRNAs to mould the DNA structure according to the functional state required. The aberrant methylation of the CpG islands located at the promoter region of specific genes is a common and early event involved in cancer development. Thus, hypermethylated DNA sequences from tumours are one of the most promising markers for early detection screenings as well as tumour classification and chemotherapy response in many types of cancer.
Notes
ISI Document Delivery No.: 316IK Times Cited: 0 Cited Reference Count: 53 Cited References: BATTAGLI C, 2003, CANCER RES, V63, P8695 BAYLIN SB, 1998, ADV CANCER RES, V72, P141 BAYLIN SB, 2000, TRENDS GENET, V16, P168 BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380 BESTOR TH, 2000, HUM MOL GENET, V9, P2395 BIRD A, 2002, GENE DEV, V16, P6 CAIRNS P, 2001, CLIN CANCER RES, V7, P2727 CHAN MF, 2001, MOL CELL BIOL, V21, P7587 CHANG YS, 2002, CLIN CANCER RES, V8, P3669 CHANG YS, 2002, CLIN CANCER RES, V8, P3796 CHAVEZBLANCO A, 2006, CANC CELL INT, V6, P2 CHEN WD, 2005, J NATL CANCER I, V97, P1124 DECACERES II, 2004, CANCER RES, V64, P6476 DECACERES II, 2006, CANCER RES, V66, P5021 DINICOLANTONIO F, 2005, BMC CANCER, V5 DULAIMI E, 2004, CLIN CANCER RES 1, V10, P6189 DULAIMI E, 2004, CLIN CANCER RES, V10, P1887 EADS CA, 2000, NUCLEIC ACIDS RES, V28, E32 EGGER G, 2004, NATURE, V429, P457 ESTELLER M, 2000, NEW ENGL J MED, V343, P1350 EVRON E, 2001, LANCET, V357, P1335 FRAGA ME, 2002, BIOTECHNIQUES, V33, P632 FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827 GAUDET F, 2003, SCIENCE, V300, P489 GLASSPOOL RM, 2006, BRIT J CANCER, V94, P1087 GOLL MG, 2006, SCIENCE, V311, P395 HENRIQUE R, 2004, EUR UROL, V46, P660 HERMAN JG, 1996, P NATL ACAD SCI USA, V93, P9821 HERMAN JG, 2003, NEW ENGL J MED, V349, P2042 HERMANN A, 2004, CELL MOL LIFE SCI, V61, P2571 HOQUE MO, 2004, CANCER RES, V64, P5511 ISSA JPJ, 1994, NAT GENET, V7, P536 ISSA JPJ, 1996, CANCER RES, V56, P3655 JAHR S, 2001, CANCER RES, V61, P1659 JERONIMO C, 2004, CLIN CANCER RES 1, V10, P4010 JONES PA, 1999, NAT GENET, V21, P163 KAGAN J, 2007, CANCER RES, V67, P4545 KIM DH, 2001, CANCER RES, V61, P3419 KOUL S, 2004, MOL CANC, V3, P16 LIANG G, 2002, CANCER RES, V62, P961 LODYGIN D, 2005, CANCER RES, V65, P4218 PALMISANO WA, 2000, CANCER RES, V60, P5954 PARKIN DM, 2001, INT J CANCER, V94, P153 ROSENBAUM E, 2005, CLIN CANCER RES, V11, P8321 SANTI DV, 1983, CELL, V33, P9 SATO N, 2003, CANCER RES, V63, P3735 SHAMES DS, 2006, PLOS MED, V3, P2244 SHEN LL, 2002, J NATL CANCER I, V94, P755 SIU LLP, 2003, BRIT J HAEMATOL, V122, P70 SUZUKI H, 2002, NAT GENET, V31, P141 SVED J, 1990, P NATL ACAD SCI USA, V87, P4692 TAKAI D, 2002, P NATL ACAD SCI USA, V99, P3740 TOKUMARU Y, 2004, CANCER RES, V64, P5982 Ibanez de Caceres, I. Cairns, P. SPRINGER; 233 SPRING ST, NEW YORK, NY 10013 USA